H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Silence Therapeutics to $75 from $80 and keeps a Buy rating on the shares post the Q3 report. The company is making steady progress with lead candidates in cardiovascular disease and rare blood cancer to provide a regular cadence of clinical data in 2024, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLN: